Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab With Alternating R-CHOP/R-DHAP in Previously Untreated Mantle Cell Lymphoma
NCT07444710Phase 1Not yet recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2026
- Primary completion
- Sep 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of glofitamab in mantle cell lymphoma (MCL), sponsored by National Cancer Institute. Primary endpoints: Incidence of adverse events up to 5 years and Dose limiting toxicity. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
glofitamab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT07444710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07444710.